BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models
TheFly reported on April 10 that Morgan Stanley slightly increased its price target on BNTX from $125 to $126 while maintaining an Overweight rating.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 951,372 | $84,557,943 | +41% | 0.01% |
| 2. | Long Focus Capital Management John B. Helmers | 624,000 | $55,461,120 | +23% | 1.46% |
| 3. | Tang Capital Management Kevin C. Tang | 470,000 | $41,773,600 | 2.12% | |
| 4. | 452,715 | $40,237,309 | +202% | 0.01% | |
| 5. | Hudson Bay Capital Management Sander Gerber | 275,000 | $24,442,000 | -27% | 0.08% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $110.56 | 50,000 | $5,527,960.00 | 399,387 | 2026-04-22 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,709,240 | $507,437,244 | 0.03% | |
| 2. | 3,793,711 | $337,185,032 | 0.27% | |
| 3. | 3,680,315 | $327,106,397 | 1.53% | |
| 4. | 3,676,791 | $326,793,184 | 0.18% | |
| 5. | 1,658,153 | $147,376,669 | 0% |